Anthem Biosciences' IPO is scheduled to open and close in 2025. It will be a Book Built Issue, with the company planning to raise approximately ₹3,395 crores through the offering. This includes a fresh issue of ₹[.] crores and an offer for sale of up to [.] equity shares, each having a face value of ₹2.

The IPO price band is set between ₹[.] and ₹[.] per share. The issue will allocate 35% for retail investors, 50% for Qualified Institutional Buyers (QIBs), and 15% for High Net-Worth Individuals (HNIs). Anthem Biosciences is expected to list on both the BSE and NSE in 2025. The IPO allotment is also scheduled for the same year.

For the financial year 2024, the company recorded a revenue of ₹1,483.07 crores, compared to ₹1,133.99 crores in 2023. The net profit stood at ₹367.31 crores in 2024, slightly down from ₹385.19 crores in 2023. Based on the financial performance, the IPO appears suitable for long-term investors.

About Anthem Biosciences IPO

Anthem Biosciences is a Contract Research and Innovation Service Provider (CRISP), equipped with facilities that can accommodate over 1,000 researchers and support the production of innovative commercial drug actives across its two locations in Bangalore, India.

Since beginning operations in 2007, the company has rapidly grown into a leading player in drug discovery, development, and manufacturing, with a balanced focus on both chemistry- and biology-based products and services.

A dedicated team of skilled chemists, biologists, and engineers ensures transparent and ethical engagement with clients. Anthem’s laboratories have supported both emerging biotech firms and major pharmaceutical companies in developing, optimizing, and testing a wide range of products, including proteins, monoclonal antibodies, peptides, large and small molecules, toxins, and more.